Search results
Showing 1006 to 1020 of 1373 results for social care
In development Reference number: GID-TA10577 Expected publication date: 21 April 2021
In development Reference number: GID-TA11482 Expected publication date: TBC
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Discontinued Reference number: GID-TA10345
Discontinued Reference number: GID-TA10297
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
In development Reference number: GID-TA11269 Expected publication date: TBC
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Discontinued Reference number: GID-TA10310
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
Discontinued Reference number: GID-TA10211
In development Reference number: GID-TA10467 Expected publication date: TBC